LH — Labcorp Holdings Inc.

Labcorp Holdings (LH) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $3.5 billion, up 5.6% year-over-year, driven by organic growth of 3.8% and acquisitions contributing 1.2%.
• Adjusted EPS: $4.07, an increase of 18% from the previous year.
• Free Cash Flow: $490 million, down from $665 million due to working capital timing.
• Enterprise Revenue Growth (2025): Over 7%, with adjusted EPS growth of 13%.
• Margins: Enterprise margins improved by 120 basis points; Diagnostics margins increased by 150 basis points.
• Book-to-Bill Ratio: Strong at 1.16 for the quarter and 1.09 for the trailing 12 months.

2. Strategic Updates and Business Highlights:

• Labcorp signed or closed 13 partnerships with health systems and local laboratories, contributing over $1 billion in revenue growth over three years.
• Significant advancements in specialty testing, with over 130 new tests launched in 2025, particularly in oncology, women's health, neurology, and autoimmune disease.
• Successful integration of Invitae, enhancing genetic testing capabilities.
• Continued expansion of Labcorp OnDemand, offering tests for over 200 biomarkers.
• Investment in a new central laboratory facility to support growth, with construction expected to begin in 2026.

3. Forward Guidance and Outlook:

• 2026 Revenue Growth Guidance: Expected to be 4.7% to 6%, with Diagnostics revenue growth projected at 5% to 6% and Biopharma Laboratory Services (BLS) revenue growth at 3% to 5%.
• Adjusted EPS Guidance for 2026: $17.65 to $18.25, implying approximately 9% growth at midpoint.
• Free Cash Flow Guidance: $1.24 billion to $1.36 billion, with expectations of being weighted towards the second half of the year.
• Anticipated margin improvements across both segments in 2026, with BLS expected to see greater expansion than Diagnostics.

4. Bad News, Challenges, or Points of Concern:

• Impact of ACA Tax Credit Expiration: Estimated to reduce diagnostic volume by about 30 basis points in 2026.
• Volume Weakness in Q4: Organic volume growth was lower than expected, attributed to reduced referrals from a key consumer genetic client and adverse weather conditions; however, this is viewed as a one-time issue.
• Early Development Business: Expected to be relatively flat in 2026, with ongoing consolidation efforts impacting revenue.

5. Notable Q&A Insights:

• Management expressed confidence in the strength of the diagnostics market and their ability to outperform it.
• Discussions around the competitive landscape highlighted a focus on specialty testing and partnerships with health systems.
• Concerns regarding the early development market were acknowledged, with plans to streamline operations and improve profitability.
• Management is advocating for the RESULTS Act to address issues related to PAMA and is prepared for upcoming data submissions.
• There is a strong pipeline for potential acquisitions, although timing may vary due to regulatory approvals.

Overall, Labcorp's performance in 2025 was strong, with positive momentum heading into 2026, despite some challenges and headwinds that could impact specific segments.